582940 Disclosed are 4-(8-(4-cycloalkyl)-8-azabicyclo[3.2.1]octan-3-yl)-3-oxo-3,4-dihydroquinoxaline derivatives as represented by the general formulae (I) and (II), or pharmaceutically acceptable salts, solvates, radiolabeled isomers, stereoisomers, enantiomers, diastereomers, other stereoisomeric forms, racemic mixtures, geometric isomers, and/or tautomers thereof, wherein: Y1 is O or S Q is selected from fused benzo or (5- or 6-membered)heteroaryl R3 is selected from -H optionally substituted alkyl or optionally substituted cycloalkyl and wherein the remaining substituents are as defined herein. Representative compounds include 4-((endo)-8-((exo)-bicyclo[3.3.1]nonan-3-yl)-8-azabicyclo[3.2.1]octan-3-yl)-3-oxo-3,4-dihydroquinoxaline-2-carboxylic acid and 4-((endo)-8-cyclononyl-8-azabicyclo[3.2.1]octan-3-yl)-3-oxo-3,4-dihydroquinoxaline-2-carboxylic acid. Also disclosed are intermediate compounds of the formulae (III), (IV) and (V) which are useful in the preparation of compounds of formula (I) or formula (II). Further disclosed is a composition comprising an effective amount of the compound as defined above, and a pharmaceutically acceptable carrier or excipient, for treating pain, a memory disorder, obesity, constipation, depression, dementia, Parkinsons disease, anxiety, cough, diarrhoea, high blood pressure, epilepsy, anorexia/cachexia, urinary incontinence, or drug abuse in an animal.
